Eddy Anglade

Eddy Anglade, MD has a diverse work experience in the pharmaceutical and medical industry. Eddy is currently serving as the Chief Executive Officer at Tenpoint Therapeutics Ltd since June 2023. Prior to this, they held the Vice President and Clinical Lead, Retina role at Janssen Research and Development, LLC from September 2019 to July 2023.

Eddy has also worked as the Vice President and Global Therapeutic Area Head, Ophthalmology at Astellas Pharma Global Development from October 2018 to September 2019. Before that, they served as the Chief Medical Officer and Therapeutic Area Head at Astellas Institute for Regenerative Medicine from February 2016 to October 2018.

In their earlier roles, Dr. Anglade worked as the Chief Medical Officer at Ocata Therapeutics, Inc. from January 2014 to February 2016. Eddy also founded and served as the Chief Medical Officer of Lux Biosciences, Inc. from May 2006 to July 2013. Additionally, they worked at Enzon Pharmaceuticals as the Vice President, Clinical Development, overseeing clinical development activities from January 2003 to April 2005.

Dr. Anglade has also worked as a Consultant at BRISTOL-MYERS SQUIBB COMPANY and EYETECH PHARMACEUTICALS INC. in the early 2000s.

Eddy Anglade, MD earned their Doctor of Medicine (M.D.) degree from Yale University School of Medicine, completing their studies from 1984 to 1989. Prior to that, they completed their undergraduate studies at Columbia University, where they received an AB in Biology from 1980 to 1984. Eddy Anglade's high school education was obtained at Regis High School, but no specific dates or degree were provided.